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ARTICLE
Clinical Study
Preoperative chemotherapy and radiotherapy concomitant to
cetuximab in resectable stage IIIB NSCLC: a multicentre
phase 2 trial (SAKK 16/08)
Alessandra Curioni-Fontecedro1, Jean Yannis Perentes2, Hans Gelpke3, Alexandros Xyrafas4, Hasna Bouchaab2, Nicolas Mach5,
Oscar Matzinger6, Nina Stojcheva2, Martin Frueh7, Walter Weder1, Richard Cathomas8, Piera Gargiulo4, Lukas Bubendorf9, Miklos Pless3,
Daniel Betticher10 and Solange Peters2 for the Swiss Group of Clinical Cancer Research (SAKK)
BACKGROUND: Neoadjuvant chemotherapy (CT) followed by radiotherapy (RT) and surgery showed a median survival of
28.7 months in resectable stage IIIB non-small-cell lung cancer (NSCLC) patients (pts). Here, we evaluate the impact of concomitant
cetuximab to the same neoadjuvant chemo-radiotherapy (CRT) in selected patients (pts) with NSCLC, stage IIIB.
METHODS: Resectable stage IIIB NSCLC received three cycles of CT (cisplatin 100 mg/m2 and docetaxel 85 mg/m2 d1, q3w)
followed by RT (44 Gy in 22 fractions) with concomitant cetuximab (250 mg/m2, q1w) and subsequent surgery. The primary
endpoint was 1-year progression-free survival (PFS).
RESULTS: Sixty-nine pts were included in the trial. Fifty-seven (83%) pts underwent surgery, with complete resection (R0) in 42
(74%) and postoperative 30 day mortality of 3.5%. Responses were: 57% after CT-cetuximab and 64% after CRT-cetuximab. One-
year PFS was 50%. Median PFS was 12.0 months (95% CI: 9.0–15.6), median OS was 21.3 months, with a 2- and 3-yr survival of 41%
and 30%, respectively.
CONCLUSIONS: This is one of the largest prospective phase 2 trial to investigate the role of induction CRT and surgery in resectable
stage IIIB disease, and the ﬁrst adding cetuximab to the neoadjuvant strategy. This trial treatment is feasible with promising
response and OS rates, supporting an aggressive approach in selected pts.
British Journal of Cancer (2019) 120:968–974; https://doi.org/10.1038/s41416-019-0447-0
BACKGROUND
Management of locally advanced NSCLC is still challenging, and
the role of surgery is mainly deﬁned by regional preferences and
local standards. While deﬁnition of stage IIIA/B has been slightly
modiﬁed through the recent 6th to 8th TMN classiﬁcation, stage
IIIB/C as deﬁned by T4 or N3 disease is characterised by a dismal 5-
year overall survival (OS) ranging between 10 and 25%, possibly
slightly higher in patients with resectable disease.1,2 Previously,
several phase 2 trials have evaluated multimodal surgical
treatment strategy, including induction chemo-radiotherapy
(CRT) followed by surgery for patients with stage IIIB disease.
Retrospective subgroup analyses of these trials, particularly of
Southwest Oncology Group (SWOG) 8805, suggest that patients
with operable stage IIIB NSCLC might present outcomes similar to
those with stage IIIA disease.3 The Swiss Group for Clinical Cancer
Research (SAKK) demonstrated previously that, in well-selected
patients, the use of neoadjuvant chemotherapy (CT) of docetaxel/
cisplatin followed by neoadjuvant accelerated radiotherapy (RT) of
44 Gy was feasible.4 Promising results of this SAKK 16/01 trial and
surgical series5,6 are the rationale for the current quadrimodal
concept, introducing cetuximab to neoadjuvant CRT. Cetuximab
was a promising targeted agent in NSCLC, at the time of designing
this clinical trial7 and in general in combination with RT.8–10 No
unexpected toxicities were reported by combining platinum-
based CT and cetuximab, or by adding cetuximab to deﬁnitive CRT
in NSCLC.11,12 This is the ﬁrst study to assess the feasibility and
activity of adding cetuximab in the induction part of a trimodality
treatment for stage IIIB NSCLC. The main objective of this trial was
to evaluate efﬁcacy and safety in patients with operable stage IIIB
NSCLC.
METHODS
Patients
Patients were enroled from 11 participating sites, with experience
in trimodality-approach, into this open-label, multicentre, pro-
spective phase 2 SAKK trial. Patients with resectable stage IIIB
(T4N0–3M0 or T1–4N3M0), as evaluated by a multidisciplinary
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tumour-board at diagnosis and according to 6th TNM classiﬁca-
tion, were considered eligible. Stages IIIB with malignant pleural or
pericardial effusion, invasion of the aorta, oesophagus, myocar-
dium, supraclavicular, scalene N3 nodes, or with satellite lesions in
the same lobe as only T4 descriptor were excluded. Baseline
assessment was performed by brain magnetic resonance imaging,
whole body PET-CT, contrast enhanced CT scan of thorax and
upper abdomen, pulmonary function test and electrocardiogram.
Lymph-node staging was performed by mediastinoscopy or EBUS
in cases of N-positive disease on PET-CT (SUV above mediastinum
background SUV) or CT (size of >10 mm in the smallest diameter),
within 42 days from registration. In case of lymph nodes not
accessible by mediastinoscopy (ATS position 5 or 6), ﬁne needle
aspiration biopsy by EBUS, TBNA or VATS was required.13,14 In case
of N-negative disease on PET-CT and CT, mediastinoscopy was
only mandatory in case of suspicion of T4 tumour invading the
trachea. Patients had to be medically ﬁt to undergo surgery and to
present sufﬁcient pulmonary reserve to allow the required surgery,
according to ESTS guidelines.15–17 Other eligibility criteria
included: age 18–75 years; WHO performance status 0 or 1;
adequate bone marrow, hepatic and renal function, as well as
heart function within 42 days from registration.18 The study was
done in accordance with the principles of the Declaration of
Helsinki. The protocol was approved by the ethics committee of
each participating site. Written informed consent was obtained
from all patients.
Procedures
CT consisted of three cycles of intravenous cisplatin (day 1 and 2,
50mg/m²) and docetaxel (85 mg/m² day 1) given every 3 weeks.
The administration of prophylactic granulocyte-colony stimulating
factor was compulsory. Dose reductions were not allowed for
cisplatin. Switch to carboplatin (target area under the curve 6) was
allowed if patients developed renal function impairment (creati-
nine clearance lower than 50mL/min), hearing loss worse ≥grade
2, or peripheral neuropathy ≥grade 3. Cetuximab was given
weekly at an initial loading dose of 400 mg/m² and then at
250mg/m² during the entire course of CT and RT. After cetuximab-
CT and before radiotherapy, positron emission tomography–
computed tomography (PET-CT), contrast enhanced computed-
tomography scan of thorax and upper abdomen, pulmonary
function testing and diffusion capacity were repeated. RT was
planned in all patients without progressive disease (PD) after
cetuximab-CT and started 3 weeks after the last CT administration.
The regimen consisted of a total dose of 44 Gy in 22 fractions of 2
Gy (PTV 1= 30 Gy, PTV 2= 14 Gy). The overall treatment duration
was 19 days. Dose prescription and recording had to comply with
the recommendations of the ICRU 50/62 quality control. Before
surgery, contrast enhanced CT scan of thorax and upper abdomen
and pulmonary function tests were obtained and each patient was
evaluated by a local multidisciplinary tumour-board for surgical
resection. Surgery was to be planned within 21–28 days after
completion of RT (study design is represented in Fig. 1). The
recommendation was to avoid pneumonectomy whenever
possible, especially in situations where a complete R0 resection
could be obtained by a parenchyma-saving procedure. Surgery
included tumour resection and systematic lymph-node dissection.
Patients whose tumours had progressed at either post-baseline
assessment were withdrawn from the study treatment but further
followed for toxicity and survival. Patients attended follow-up
visits 1 month after surgery, then every 3 months for 2 years, every
6 months for 3 years, until 5 years after surgery or treatment
termination, unless clinically indicated otherwise. During visits
patients were assessed for toxicity and chest CT every 3 months
for the ﬁrst 2 years, afterwards every 6 months until 5 years. WHO
criteria were used to assess tumour response; assessments were
done locally by the trial investigators. Adverse events were graded
according to the 1994 revised version 3.0 of the National Cancer
Institute of Health CTCAE guidelines. Moreover, the ﬁrst 25
patients were strictly evaluated regarding safety and toxicity and
1 month after operation of the 25th enroled patient, an interim
safety analysis was performed by an IDMC.
Statistical analysis
The primary endpoint was progression-free survival (PFS) at 1 year,
deﬁned as the absence of disease progression/relapse or death at
1 year ( ± 1 month) after registration.
Secondary endpoints included: treatment-related death during
cetuximab-CT, cetuximab-RT and peri-operatively (until 30 days
after surgery); tumour response after cetuximab-CT and after
cetuximab-RT; complete pathological response (pCR); OS, deﬁned
as the time from registration until death due to any reason;
adverse events (AEs); operability (based on a multidisciplinary
tumour-board decision, under exhaustive evaluation of cardiac
and pulmonary function according to ESTS/ATS guidelines);
resection margins; failure pattern (deﬁned as location of ﬁrst
progression).
Sample size was calculated based on PFS at 1 year. The PFS rate
of ≤50% was considered uninteresting and ≥65% promising.
Fleming-A’ Hern single-stage phase 2 procedure with a power of
80%, a one-sided signiﬁcance level of 5% and a sample size of 69
evaluable patients was chosen.
For the primary endpoint, the PFS rate at 1 year together with
its two-sided 90% CI was presented using the binary variable
showing the information of progression at 1 year. PFS rate at 1
year was also calculated using the Kaplan–Meier estimator at 1 ear
from registration together with both 90 and 95% two-sided CI, to
be able to make comparisons with the results of the binary
variable and to put our results in perspective to results in the
published literature. Analyses were done with SAS version 9.4 and
R version 3. The analysis of the primary endpoint was performed in
both the intention-to-treat (ITT) population and the per protocol
population (PP), deﬁned as a subset of patients of the ITT
population excluding patients who did not receive full trial
treatment or patients who had major protocol violations in a
prospectively planned exploratory analysis. For the secondary
endpoints expressed as rates, the point estimates of the rate
together with the associated two-sided 95% CI were calculated.
For the secondary endpoints expressed as time-to-event end-
points, the median value was estimated using the Kaplan–Meier
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method along with a two-sided 95% CI. The type and number of
events for each endpoint were presented descriptively by
frequency and percentage. All data were collected and analysed
at the SAKK Coordinating Centre in Berne, Switzerland. This trial is
registered with ClinicalTrials.gov, number NCT01059188.
RESULTS
Between June 2010 and January 2016, 69 patients with
resectable Stage IIIB NSCLC were included in the trial at 11
centres in Switzerland. One of the 69 patient was found to be
misdiagnosed with lung cancer after having received full
treatment and a supporting statistical analysis has been
performed excluding this patient. Analysis for primary endpoint
(1-year PFS) and toxicity is reported for the ITT population.
However, 16 out of the accrued 69 patients were not included in
the PP set (due to toxicity, early progression or death) and are
not included in the analysis of secondary endpoints. Patients’
baseline and tumours characteristics are shown in Table 1.
Twenty-seven (39%) patients had a T1–3N3M0 disease, 37 (54%)
a T4N0–2M0 stage and 5 (7%) a T4N3M0 disease. The majority of
patients had good performance status. Adenocarcinoma was the
predominant histology (49%).
Treatment delivery is presented in Fig. 2. Sixty-two out of
69 patients (90%) completed the three cycles of cetuximab-CT. A
total of 197 cycles of cetuximab-CT were delivered with a median
treatment duration of 63 days (21–83). Ninety percent of patients
completed the three cycles of chemotherapy-cetuximab with a
relative dose intensity for cetuximab of 90%, for cisplatin of 99.2%,
for docetaxel of 98.5% (Supplementary Table 1). Eleven patients
switched from cisplatin to carboplatin due to worsening of renal
function (in four cases), hearing loss (in three cases), electrolytes
disorders (three cases) and gastrointestinal toxicity (1 case).
Reasons for not completing the three cycles were: death due to
infection (in two cases), infection, haemoptysis, hepatitis B
reactivation, oesophageal fungal infection and PD. Cetuximab-RT
was planned for 63 patients. Two patients did not receive RT, due
to toxicity and refusal after cetuximab-CT, respectively. RT
schedule was administered for a median period of 20 days
(19–25 days). Ninety-ﬁve percent of the 61 patients received
radiotherapy per protocol with 22 fractions of 2 Gy with planed
target volumes (respectively, with 30 Gy and 14 Gy). Cetuximab
was given with a median duration of 21 days (7–42 days). In total,
52 (83%) completed the 3-weeks of cetuximab-radiotherapy. The
response rate after cetuximab-CRT in these 52 patients was 64%
(95% CI: 51–75%), see Table 2.
Toxicity to cetuximab-CT was in the expected proﬁle and range,
including grade 3/4 neutropenia in 33% of patients, febrile
neutropenia in 1%, renal function impairment grade 3 in 7%;
grade 3 and 4 rash in 16% of patients, grade 3 diarrhoea in 15%.
Drug related AEs leading to discontinuation of cetuximab-CT were
observed in 9% of the patients. One patient died due to cerebral
nocardiosis. Toxicity during cetuximab-RT included grade 2
esophagitis in 3% of patients, pneumonitis in 1.6% of patients.
Thirteen percent of patients (8 out of 61 undergoing cetuximab-
RT) discontinued the treatment due to adverse events (Supple-
mentary Table 2).
The median time from registration to surgery was 17 weeks
(range 8–21 weeks). Sixty-three out of the 69 ITT patients were
considered operable (91%, 95% CI: 82–97%), but only 57 out of
these 63 underwent surgery 90% (95% CI: 80–96%), related to
disease progression (3), worsening of lung function (1) and
absence of resectability (2). The median duration of patient
hospitalisation for surgery was 13 days (3–113 days). The type of
surgery (including bilobectomy, lobectomy or pneumonectomy),
together with surgical outcomes, are summarised in Table 3 and
Supplementary Table 3. Rate of pathologic complete response was
29% (95% CI: 19–41%) for all 69 patients. Calculated only for the
R0/R1 resected patients, it was 35% (20 out of 57) (95% CI:
23–50%). No correlation was found between the rate of R0
resection and clinical nodal stage (N0–2 vs. N3; Fisher’s exact test
p= 0.471).
Three patients died after surgery, two of them within 30 days
after surgery with hypoxaemia and sepsis, and one 38 days after
surgery with massive pulmonary haemorrhage. Thirty-day-
postoperative mortality rate was 3.5% (2 out of 57). At the time
of this analysis patients were followed-up for a median time of
32 months (IQR: 27–61 months). Median PFS was 12 months (95%
CI: 9–16 months) (Fig. 3a). At the time of the analysis there were 43
events, mainly local or distant progression (86%). Among the 26
censored patients, ﬁve (19%) were followed for at least 5 years, ten
(39%) were censored due to start of a new treatment and ten
(39%) were still under follow-up.
One-year PFS rate, calculated according to the protocol as a
binomial variable, was 38% (90% CI: 28–48%). However, using the
Kaplan–Meier estimators, 1-year PFS rate was 50% (95% CI:
37–62%; 90%CI: 39–60%).
Table 1. Patient characteristics
Variable Overall (N= 69)
n (%)
Age (years)—median (min–max) 69 (36–73)
Sex
Female 16 (23.2%)
Male 53 (76.8%)
Tumour IIIb stage
T1 N3 M0 5 (7.2%)
T2 N3 M0 18 (26.1%)
T3 N3 M0 4 (5.8%)
T4 N0 M0 18 (26.1%)
T4 N1 M0 2 (2.9%)
T4 N2 M0 17 (24.6%)
T4 N3 M0 5 (7.2%)
Lymph-node staging by mediastinoscopy
No 1 (1.4%)
Yes 57 (82.6%)
Not available 11 (15.9%)
Patient considered operable
Yes 69 (100.0%)
WHO PS at entry
0 46 (66.7%)
1 23 (33.3%)
Intervention planned at Tumour-board before inclusion
Bilobectomy 11 (15.9%)
Lobectomy 36 (52.2%)
Pneumonectomy 15 (21.7%)
Missing 7 (10.1%)
Histology
Adeno-NSCLC 34 (49.3%)
Large-cell NSCLC 1 (1.5%)
Poorly differentiated NSCLC 5 (7.2%)
Squamous NSCLC 28 (40.6%)
Missinga 1 (1.5%)
Pack-years of smoking—median (min–max) 40 (3–150)
aHistology of tumour could not be deﬁned in pathology report as material
was not sufﬁcient for evaluation
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Median OS was 21 months (95% CI: 14–25 months). The
Kaplan–Meier curve of OS can be found in Fig. 3b; estimated OS at
1, 2 and 3 years was 70% (57–79%), 41% (29–53%) and 30%
(19–42%), respectively.
At the time of the analysis there were 46 deaths, mostly related
to progression (80%). Among the 23 censored patients, 6 (26%)
were followed for at least 5 years and 16 (70%) were still under
follow-up.
ACCRUED (n = 69*)
Chemo-cetuximab (n = 69) Radio-cetuximab (n = 63)
Cetuximab
Radiotherapy
Transf to surgery: 1
Transf to FU (n = 3) Transf to FU (n = 1)
Surgery (N = 63)
Performed (n = 57)
Nor performed (n = 6)
Follow-up (n = 67)
Dead (n = 44)
Alive (n = 22)
Lost to FU (n = 1)
Not given (n = 2)
Completed (n = 62)
Not completed (n = 7)
REASONS:
Progression: 1
Toxicity: 4
Death: 2
Completed (n = 52)
Not completed (n = 11)
REASONS:
Patient’s wish: 2
Toxicity: 8
Refused: 1
REASONS:
Toxicity: 1
Refused: 1
REASONS:
Progression: 3
Toxicity: 1
Other: 2
REASONS:
Refusal
REASONS:
Toxicity: 2
Progression: 1
REASON:
Toxicity
Fig. 2 Flow Chart of the trial. Asterisk indicates a patient was mistakenly registered and was not included in the total accrual
Table 2. Response after chemotherapy-cetuximab (CTC) and
radiotherapy-cetuximab (RTC)
Response N % Response rate 95% CI
After CTC PR 39 56.5 56.5% (44.0–68.4%)
SD 27 39.1
PD 1 1.4
NE 2a 2.9
After RTC PR 44 63.8 63.8% (51.3–75.0%)
SD 12 17.4
PD 3 4.3
NE 10 14.5
aOne patient stopped due to haemorrhagic tumour and one patient
stopped due to death. These events are usually counted as PD (progressive
disease), PR (partial response), SD (stable disease), NE (not evaluable)
Table 3. Surgery results
Variable Overall (N= 69)
n (%)
Operability
No 6 8.7
Yes 57 82.6
NE 6 8.7
Resection
R0 42 60.9
R1 14 20.3
NE 13 18.8
Pathologic complete response
No 34 49.3
Yes 20 29.0
No R0/R1 resected 13 18.8
Missing 2 2.9
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DISCUSSION
About a third of patients with newly diagnosed NSCLC present
with locally advanced disease. Optimal management of stage III
NSCLC remains a matter of debate after several trials evaluating
the role of surgery after C or CRT as compared to deﬁnitive radical
CRT.19,20,4,21–25 The SAKK group previously randomised 232 stage
IIIA/N2 NSCLC patients to induction chemo-radiotherapy vs.
chemotherapy with a similar median event-free survival in the
two groups.25 While radiotherapy did not add any beneﬁt to
induction chemotherapy followed by surgery, this trial suggested
that one optimal local treatment is sufﬁcient to treat resectable
stage IIIA/N2 NSCLC.
The European Society of Medical Oncology (ESMO) does not
recognise a clear beneﬁt for one of the local treatments and the
choice of local treatment modality may vary across countries and
centres. For the American Society of Clinical Oncology (ASCO),
deﬁnitive CRT is recommended in patients with good performance
status with a median survival that typically reaches 15 to 20 months.
Multimodal approach of stage IIIB patients, including CRT and
surgery reported a median OS of 17 months after CRT with surgery
from the SWOG 8805 trial, with a survival rate of 39% at 2-years.26
Next the SAKK 16/01 trial, showed a median OS of 29 months and
a 2-years OS of 52%. Such results led to the development of the
here reported study (SAKK 16/08), resulting in a median OS of
21 months with a 2-year OS of 41%, reproducing the results of the
SWOG trial. While in the SWOG trial, on the contrary of the SAKK
16/01 and SAKK 16/08 trials, supraclavicular lymph-node involve-
ment and involvement of mediastinal structures were permitted,
only 62% underwent surgery, compared to 71% from the SAKK 16/
01 and 91% from the SAKK 16/08. This reﬂects the complexity of
patients’ selection for surgery in stage IIIB. A higher rate of
resectability might also be explained by the use of systematic PET-
CT scans at staging in the SAKK 16/08.27 While PET was only used
in the last 60% of patients enroled in the SAKK 16/01, SAKK 16/01
and 16/08 differed in the addition of cetuximab to induction
treatment. Interestingly, the higher pathological complete
response rate in the present trial compared to the SAKK 16/01
(29% vs. 13%, respectively), did neither result in an improved
response rate to induction (64% vs. 59%), nor in 1-year PFS (50%
vs. 54%) nor median OS (21 vs. 29 months). Toxicity to induction
therapy was in the expected range and comparable to the SAKK
16/01 trial. Perioperative mortality in this trial was low and
comparable to the SAKK 16/01 trial (4% in SAKK 16/08 vs. 6% in
SAKK 16/01) and comparable to the SWOG 8805 trial (5.2%) The
outcome of highly selected patients in both SAKK trials remains
better than previously reported using deﬁnitive CRT.
The use of EGFR monoclonal antibodies in combination
with frontline platinum-based chemotherapy allows for an
improvement in OS, such beneﬁt was sufﬁcient for FDA to
approve necitumumab in this setting, however, considered as a
marginal beneﬁt.7,28 Following encouraging preclinical and early
clinical trials results, controlled randomised trials were unable to
demonstrate improved outcome of the cetuximab arms combined
with CRT compared to CRT alone in stage III NSCLC.29,30 The
treatment regimen presented here (SAKK 16/08) however differs
from the above-mentioned studies due to the inclusion restricted
to selected resectable stage IIIB patients, the surgical approach
and the absence of maintenance strategy, in order to limit
perioperative toxicity. As EGFR expression in tumours might vary
after induction,31,32 maintenance cetuximab might inﬂuence the
outcome of patients with high EGFR expression.30 In the present
study, we did not assess EGFR expression status of patients due to
potential bias related to the small size of the cohort.
Compared to historical series of stage IIIB treated with CRT
therapy, our study shows a high disease control rate. However,
there are some limitations due to the absence of randomisation
with a control group. Moreover, patients were highly selected,
being candidates for surgery with good performance status, as
well as pulmonary reserve and heart function. Our results suggest
that careful patient selection and intensive multimodal therapy
can lead to better results than the ones obtained with deﬁnitive
CRT, and that stage IIIB disease can be cured.
Novel approaches in non-resectable stage III NSCLCs have been
recently reported in the PACIFIC trial where patients were treated
by CRT and randomised to receive a PD-L1 inhibitor, namely
durvalumab.33,34 The primary endpoint of progression-free survival
was met with a median of 17.2 months vs. 5.6 months in the
durvalumab group compared to control and a 2 year OS of 63%.
While these patients were considered non-resectable based on
local standards, our study offers novel perspectives in the multi-
modal management of stage III NSCLC and might impact the
debate about the role of surgery in stage III NSCLC. Next generation
of trials combining immunotherapies in the context of stage III
deﬁnitive CRT are in preparation or recruitment stage. Novel
treatment protocols that include induction chemo-immunotherapy
followed by surgery and immunotherapy maintenance administra-
tion are also under investigation in early NSCLC, including stage IIIA.
Knowing the high risk of distant relapse in stage III NSCLC,
combination of an optimal local control and immunotherapy-
mediated immunogenic cell death will certainly provide the most
interesting long-term beneﬁt in locally advanced lung cancer.
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and 30% (19–42%), respectively
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